Tumor-bearing mice were injected intraperitoneally with bevacizumab (Bev: 5 mg/kg, 100 μg/mouse, Roche Diagnostics GmbH, Germany) and tail vein with anti-PD-1 antibody (2.5 mg/kg, 50 μg/mouse, Leinco Technologies, USA) (anti-PD-1 + Bev) or in combination (LLCvac + anti-PD-1 + Bev) twice weekly for 2 weeks. Here, PDCD1 is linked to neoplasm.